Back to Sites Bronx-Lebanon Hospital IMPAACT Site Number 5114 Address Bronx-Lebanon Hosp. IMPAACT CRS 1685 Morris Ave Suite 1 G Bronx, NY 10457 United States of America IMPAACT Members at this Site Martha Cavallo CRS Coordinator Studies at this Site P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure Study Status Enrolling IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status Enrolling IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure Study Status Enrolling IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Treatment Study Status Enrolling IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Treatment Study Status In Development
P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure Study Status Enrolling
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status Enrolling
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure Study Status Enrolling
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Treatment Study Status In Development